{"id":1626,"date":"2020-08-26T09:35:03","date_gmt":"2020-08-26T09:35:03","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/new-stago-webinar-announcement\/"},"modified":"2021-01-08T11:12:19","modified_gmt":"2021-01-08T11:12:19","slug":"new-stago-webinar-announcement","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/new-stago-webinar-announcement\/","title":{"rendered":"New Stago Webinar announcement"},"content":{"rendered":"
How to diagnose and manage Heparin-Induced Thrombocytopenia (HIT)?<\/strong> Type II Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin<\/strong> treatment. Although rare, this complication can be serious and possibly life threatening<\/strong>.<\/p>\n Approximately one third of hospitalized patients are exposed to heparins. It is therefore of great importance to know how to:<\/p>\n This webinar will focus on HIT pathophysiology<\/strong>, and will outline the necessity of an accurate diagnosis<\/strong> and how it can be achieved. Alternative anticoagulant treatment<\/strong> options will also be discussed.<\/p>\n This 30-minute presentation will be followed by a 15-minute live chat with the speaker<\/strong>.<\/p>\n Pr Gruel is the Head of the Hematology Department<\/strong> at Trousseau University Hospital in Tours and is also leading the Hemophilia Care Center<\/strong>. He is currently the President of GEHT<\/strong> (French study Group on Haemostasis and Thrombosis), and Chairman<\/strong> of the ISTH Scientific and Standardization Committee on Platelet Immunology<\/strong>.<\/p>\n Save the date! Friday January 31st 2014 at 4:00 p.m. CET (Central European Time)<\/p>\n To attend this webinar, please register at www.stagowebinars.com<\/link>.<\/p>\n","protected":false},"excerpt":{"rendered":" How to diagnose and manage Heparin-Induced Thrombocytopenia (HIT)? by Pr Yves Gruel – Professor of Hematology, Trousseau Hospital and University Francois Rabelais, Tours (France) Type II Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin treatment. Although rare, this complication can be serious and possibly life threatening. Approximately one third of hospitalized patients are […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-1626","post","type-post","status-publish","format-standard","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1626"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=1626"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1626\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=1626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=1626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=1626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nby Pr Yves Gruel – Professor of Hematology, Trousseau Hospital and University Francois Rabelais, Tours (France)<\/p>\n\n
\n
\nApart from his clinical activity focusing on bleeding and thrombotic disorders<\/strong>, his main research topics are today heparin-induced thrombocytopenia<\/strong> (HIT) and the role of specific coagulation proteins in cancer<\/strong>.<\/p>\n